Skip to main content
Signal8

ENDONOVO THERAPEUTICS, INC. (ENDV)

Endonovo Therapeutics, Inc., a biotechnology company, specializes in the development, manufacturing, and distribution of non-invasive electroceutical medical devices designed for regenerative medicine applications. The company's primary offering is SofPulse, an advanced non-invasive therapeutic device that employs electroceutical technology. SofPulse is engineered to provide palliative relief for various conditions, including soft tissue injuries, chronic wounds, and post-operative pain and edema. Beyond these applications, Endonovo's electroceutical medical device is also utilized in treating a broad spectrum of other ailments. These include inflammation, various types of wounds, cardiovascular diseases, chronic kidney and liver disorders (such as non-alcoholic steatohepatitis), peripheral artery diseases, and ischemic stroke. Furthermore, its technology is deployed in managing central nervous system disorders like traumatic brain injury, acute concussions, post-concussion syndrome, and multiple sclerosis. Endonovo Therapeutics, Inc. was founded in 2008 and maintains its headquarters in Woodland Hills, California.

Sector: Electromedical & Electrotherapeutic Apparatus

Industry: Biotechnology

Endonovo Therapeutics, Inc. logo

Endonovo Therapeutics, Inc.

OTC:ENDVHealthcare
Mkt Cap$32K
Float240.02M
O/S318.75M
Inst Own-
Dilution
FormDescription
SEC STAFF ACTION
SEC Filing
15-12G
SEC Filing
8-K
1.01,9.01
10-Q/A
Quarterly Report (Amended)
10-Q
Quarterly Report
8-K
1.01,9.01
NT 10-Q
SEC Filing
8-K
8.01,9.01
1-A/A
SEC Filing
10-Q
Quarterly Report
NT 10-Q
SEC Filing
1-A/A
SEC Filing
10-Q
Quarterly Report
NT 10-Q
SEC Filing
10-K
Annual Report
NT 10-K
SEC Filing
8-K
1.01,9.01
10-Q
Quarterly Report
NT 10-Q
SEC Filing
8-K
1.01,9.01
10-Q
Quarterly Report
NT 10-Q
SEC Filing
10-Q
Quarterly Report
NT 10-Q
SEC Filing
1-A/A
SEC Filing

1-25 of 502

…